MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Genomic Health Company Profile (NASDAQ:GHDX)

Consensus Ratings for Genomic Health (NASDAQ:GHDX) (?)
Ratings Breakdown: 4 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $30.25 (9.92% upside)

Analysts' Ratings History for Genomic Health (NASDAQ:GHDX)
Show:
DateFirmActionRatingPrice TargetActions
8/28/2015Raymond JamesUpgradeUnderperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/5/2015Canaccord GenuityReiterated RatingHold$28.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/28/2015Credit SuisseReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015JMP SecuritiesLower Price TargetMarket Outperform$36.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Canaccord GenuityReiterated RatingHold$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2015William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2015JMP SecuritiesBoost Price TargetMarket Outperform$34.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2015Canaccord GenuitySet Price TargetHold$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/19/2014Wells Fargo & Co.Initiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014Credit SuisseReiterated RatingNeutral$28.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2014Canaccord GenuityReiterated RatingHold$27.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2014Bank of AmericaReiterated RatingBuy$28.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2014Canaccord GenuityReiterated RatingHold$30.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2014JPMorgan Chase & Co.Reiterated RatingNeutral$29.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/7/2014Credit SuisseDowngradeOutperform -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2014Bank of AmericaDowngradeUnderperform$30.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2014JMP SecuritiesLower Price TargetOutperform$38.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2014Jefferies GroupLower Price Target$33.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2013BMO Capital MarketsBoost Price TargetUnderperform$18.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2013Canaccord GenuityLower Price TargetHold$35.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2013William BlairUpgradeMarket Perform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/1/2013Bank of AmericaDowngradeNeutral -> Underperform$36.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/23/2013Raymond JamesDowngradeMarket Perform -> UnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 9/1/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha